Sunshine Biopharma, Inc. (SBFM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 4 | 24 | 35 | 36 | 35 | 36 |
| Operating profit | $m | -4 | -5 | ||||||
| Net profit | $m | -3 | -12 | -27 | -5 | -5 | -6 | -6 | -1 |
| EPS reported | $ | -14.40 | -10.15 | ||||||
| Operating cashflow per share | $ | -12.82 | -3.91 | ||||||
| Capex per share | $ | 0.42 | 0.54 | ||||||
| FCF per share | $ | -13.24 | -3.37 | ||||||
| Free cash flow | $m | -6 | -5 | ||||||
| Net debt | $m | -9 | -14 | ||||||
| Book value equity | $m | 23 | 28 | ||||||
| Book value per share | $ | 55.42 | 20.17 | ||||||
| Number of shares | m | 0.42 | 1.37 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.22 | 0.19 | ||||||
| P/S LTM | x | 0.14 | 0.14 | ||||||
| P/FCF LTM | x | -0.93 | -1.11 | ||||||
| EV/EBITDA LTM | x | 0.57 | 0.61 | ||||||
| EV/Sales LTM | x | -0.09 | -0.31 | ||||||
| Earnings Yield LTM | % | -1.17% | -3.71% | ||||||
| FCF Yield | % | -107.67% | -89.92% | ||||||
| Quality | |||||||||
| ROE | % | -25.94% | -24.23% | ||||||
| ROIC | % | -18.78% | +1.96% | ||||||
| Operating margin | % | -12.34% | -14.71% | ||||||
| Gross margin | % | +32.84% | +29.80% | ||||||
| FCF/Sales | % | -15.16% | -13.01% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +4.11% | +1.36% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -6.78 | -6.78 | ||||||
| Net Debt/EBITDA | x | 1.48 | 2.61 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +4.22% | 0.00% | ||||||
| Net debt/Equity | x | -0.39 | -0.50 | ||||||
| Gross debt/equity | x | 0.04 | 0.02 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free